CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 9, 2016
Result type: Reports
Project Number: SE0485-000
Product Line: Reimbursement Review

Generic Name: Etanercept

Brand Name: Brenzys

Manufacturer: Merck Canada Inc.

Therapeutic Area: Rheumatoid arthritis, Ankylosing spondylitis

Indications: Rheumatoid arthritis, ankylosing spondylitis

Submission Type: Initial

Project Status: Complete

Biosimilar: Yes

Date Recommendation Issued: October 25, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions